Skip to Content

Join the 'Osteolytic Bone Metastases of Breast Cancer' group to help and get support from people like you.

Osteolytic Bone Metastases of Breast Cancer News

Related terms: Bone Metastases of Breast Cancer

New Drug May Brighten Outlook for Advanced Breast Cancer

Posted 16 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 16, 2016 – A recently approved drug can help slow the progression of advanced breast cancer, a new clinical trial confirms. The drug, called palbociclib (Ibrance), was approved in the United States last year for treating advanced cases of ER-positive breast cancer. That means the cancer uses the hormone estrogen to help fuel its growth. The approval was based on an earlier-stage study where the drug, used along with a standard drug called letrozole (Femara), helped keep women's cancer at bay. Palbociclib doubled the time patients remained progression-free compared to letrozole alone. The new findings, published in the Nov. 17 New England Journal of Medicine, confirm the earlier results in a larger group of women. "We found that the degree of clinical benefit was, again, remarkable," said lead researcher Dr. Richard Finn, an assistant professor of medicine at the ... Read more

Related support groups: Breast Cancer, Femara, Breast Cancer, Metastatic, Letrozole, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Ibrance, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer, Palbociclib

Vitamin D May Affect Breast Cancer Survival

Posted 10 Nov 2016 by Drugs.com

THURSDAY, Nov. 10, 2016 – Vitamin D levels may affect breast cancer patients' chances of survival, a new study suggests. Researchers analyzed data from nearly 1,700 breast cancer patients in California and found that higher vitamin D levels at diagnosis were associated with better overall survival. This link was strongest in premenopausal women. Researchers found lower vitamin D levels in patients with advanced-stage tumors and the lowest levels in premenopausal women with triple-negative cancer. Triple-negative cancer is the most common type of breast cancer found in women with changes in a gene called BRCA1. While the findings are consistent with previous studies, other factors may play a role and the study does not prove cause and effect, the researchers noted. "Our findings provide compelling observational evidence for inverse associations between vitamin D levels and risk of ... Read more

Related support groups: Breast Cancer, Vitamin D Deficiency, Breast Cancer, Metastatic, Breast Cancer, Prevention, Caltrate 600 with D, Breast Cancer - Palliative, Citracal + D, Calcium/Vitamin D, Rickets, Osteolytic Bone Metastases of Breast Cancer, Citracal Petites, Oysco 500 with D, Calcium 600 D, Citracal Creamy Bites, Calcet, Oyster Shell Calcium, Calcarb with D, Dical-D, Caltrate Colon Health, Oysco D with Calcium

Breast, Cervical Cancer More Deadly in Developing Nations: Report

Posted 2 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 2, 2016 – Women in developing countries are more likely to die of breast and cervical cancer than those in richer nations, researchers report. But, they added, many of the deaths in these low- and middle-income countries could be prevented with cost-effective treatment. "The global community cannot continue to ignore the problem – hundreds of thousands of women are dying unnecessarily every year, and the need for affordable access to cancer care is projected to increase in the coming decades, as many of the poorest countries face rising rates of cancers," said study co-author Richard Sullivan. Sullivan is a professor of cancer and global health at King's College London in England. The number of breast cancer cases diagnosed worldwide could almost double, from 1.7 million in 2015 to 3.2 million by 2030 if urgent action is not taken, the researchers said. Meanwhile, the ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer

'Ppl, I Have Breast Cancer'

Posted 28 Jul 2016 by Drugs.com

THURSDAY, July 28, 2016 – Women who communicated via social media after a breast cancer diagnosis and received information and/or support about treatment approaches were happier with their ultimate decisions, a new study finds. Researchers surveyed thousands of women not long after they learned they had breast cancer. Those who turned to online resources – whether to share the news or gain information or support – felt more satisfied with their treatment, the study found. The researchers worry that certain breast cancer patients – especially older ones, minorities and those with lower levels of education – will miss out on the possible benefits of going online. "Our findings highlight an unmet need in patients for decisional support when they are going through breast cancer treatment," said lead study author Lauren Wallner, an assistant professor of general medicine at the ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Breast Cancer, Prevention, Breast Cancer - Palliative, Diagnosis and Investigation, Osteolytic Bone Metastases of Breast Cancer

Innovative Trials Produce Promising Breast Cancer Drugs

Posted 9 Jul 2016 by Drugs.com

THURSDAY, July 7, 2016 – An innovative set of clinical trials have identified two drugs that could provide a fighting chance for women with advanced breast cancer. The drugs, neratinib and veliparib, both appear effective in helping women diagnosed with stage 2 or 3 breast cancer, researchers report. These are the first two drugs to come out of the I-SPY clinical trials, a research effort intended to streamline drug testing by better guiding treatments to those who would most benefit from them, said one of the study authors, Dr. Laura Esserman. She is director of breast cancer care at the University of California, San Francisco's Comprehensive Cancer Center. The results: Neratinib halted the spread of cancer in 56 percent of women with HER2-positive, hormone-receptor-negative breast cancer, compared with 33 percent of a control group receiving standard chemotherapy alone. Veliparib ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer

Why Breast Cancer Survivors Should Exercise

Posted 8 Jul 2016 by Drugs.com

FRIDAY, July 8, 2016 – Excessive stress can lead to memory problems among breast cancer survivors, but exercise can help, according to new research. "We found moderate to vigorous physical activity actually benefits women psychologically and that, in turn, helps their memory," said the study's lead author, Siobhan Phillips. She is assistant professor of preventive medicine at Northwestern University Feinberg School of Medicine in Chicago. Post-cancer memory issues are often attributed to chemotherapy or radiation treatments, known as "chemo brain." However, the new study findings suggest "these self-reported memory problems may be in part emotionally related," Phillips said in a university news release. "These women are frightened, stressed, fatigued, tapped out emotionally and have low self-confidence, which can be very mentally taxing and can lead to perceived memory problems," she ... Read more

Related support groups: Cancer, Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer

Smoking May Hinder Common Breast Cancer Treatment

Posted 24 Jun 2016 by Drugs.com

FRIDAY, June 24, 2016 – Smoking may blunt the effectiveness of a certain kind of breast cancer treatment, new research suggests. Among breast cancer patients taking a class of drugs called aromatase inhibitors, smokers had a three times greater risk of their cancer returning than nonsmokers, the investigators found. However, the study could not prove a cause-and-effect link. Smoking had little or no effect on the benefit of other drugs, such as chemotherapy or tamoxifen, or radiation treatment, the study authors added. "These findings need confirmation. If confirmed, smoking status should be taken into consideration when selecting the type of [breast cancer] therapy," said lead researcher Helena Jernstrom. She is an associate professor of experimental oncology at Lund University Cancer Center in Sweden. Common aromatase inhibitors include Arimidex (anastrozole), Aromasin (exemestane) ... Read more

Related support groups: Smoking, Breast Cancer, Smoking Cessation, Arimidex, Femara, Breast Cancer, Metastatic, Anastrozole, Letrozole, Aromasin, Exemestane, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer, Testolactone, Teslac

U.S. Black Women Get Less Care to Prevent Breast Cancer Return

Posted 7 Jun 2016 by Drugs.com

TUESDAY, June 7, 2016 – Black breast cancer survivors in the United States are less likely than white or Hispanic women to get follow-up genetic screening and surgeries that can help prevent a return of cancer, new research finds. Among more than 1,600 women diagnosed by age 50, almost twice as many whites were tested for critical BRCA gene mutations as blacks, the researchers found. BRCA mutations raise the lifetime risk of a second breast cancer as much as 50 percent and risk of ovarian cancer by up to 44 percent, the study authors noted. Also, black women were less likely to undergo preventive mastectomy or removal of the ovaries, even though those procedures are known to reduce the risk of a second breast cancer or ovarian cancer, the findings showed. "I hope that our findings will raise awareness of disparities pertaining to inherited cancer predispositions, that exist across the ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Ovarian Cancer, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer

Longer Use of Certain Drugs Cuts Recurrence for Breast Cancer Survivors

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – Many survivors of breast cancers that are sensitive to estrogen are advised to take hormone-suppressing drugs such as tamoxifen for five years, to cut their odds for a recurrence. Tamoxifen can have onerous side effects, however. Now, new research finds that taking an alternative, and less troublesome, class of medications for a full decade can reduce the risk for recurrence even more – without affecting a woman's quality of life. The newer class of hormone-suppressing drugs are called aromatase inhibitors, and include drugs such as letrozole (Femara), anastrozole (Arimidex) and exemestane (Aromasin). "Aromatase inhibitors do not have all the side effects of tamoxifen and overall are much better tolerated than tamoxifen," explained one breast cancer expert, Dr. Stephanie Bernik. She believes the new study supports the benefit of aromatase inhibitors, and "women ... Read more

Related support groups: Breast Cancer, Tamoxifen, Arimidex, Femara, Breast Cancer, Metastatic, Anastrozole, Letrozole, Aromasin, Exemestane, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer, Tamoxifen Hexal, Tamoxen, Genox, Nolvadex D, Tamofen, Tamosin, Nolvadex

Acupuncture May Ease Hot Flashes for Breast Cancer Patients

Posted 29 Mar 2016 by Drugs.com

MONDAY, March 28, 2016 – Acupuncture can help alleviate the often-debilitating hot flashes that afflict many breast cancer patients, new Italian research says. Noting that hot flashes are a fact of life for many women with breast cancer, the investigators found that pairing lifestyle advice with weekly acupuncture sessions dramatically improved the women's quality of life. "Acupuncture together with enhanced self-care for three months is effective in reducing hot flashes in women with breast cancer," said study author Giorgia Razzini, a clinical trial project manager in the oncology unit of Ospedale di Carpi (Carpi Hospital), in Bologna, Italy. And because hormone treatment for breast cancer typically makes the hot flash experience even worse, Razzini added, acupuncture could be a useful tool for helping such patients "stay on their therapy and improve their quality of life." Razzini ... Read more

Related support groups: Hot Flashes, Breast Cancer, Menopausal Disorders, Postmenopausal Symptoms, Breast Cancer, Metastatic, Perimenopausal Symptoms, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer

Drug Duo May Rapidly Shrink Breast Tumors in Some Patients

Posted 10 Mar 2016 by Drugs.com

THURSDAY, March 10, 2016 – A two-drug combo quickly shrinks certain breast cancer tumors before surgery or chemotherapy in some women, British researchers report. The specific breast cancer is called human epidermal growth factor receptor 2 (HER2) positive. The drug combination – lapatinib (Tykerb) and trastuzumab (Herceptin) – shrank HER2-positive tumors significantly in less than two weeks after diagnosis, the study authors said. In some cases, evidence of the cancers disappeared, the researchers added. "A combination of two anti-HER2 therapies – Tykerb and Herceptin – induce tumor regression or disappearance in 25 percent of HER2-positive cancers in 11 days," said lead researcher Dr. Nigel Bundred. He is a professor of surgical oncology at the University of Manchester in England. Potentially, women who respond to this treatment combination might be able to avoid chemotherapy, he ... Read more

Related support groups: Cancer, Breast Cancer, Breast Cancer, Metastatic, Herceptin, Breast Cancer, Prevention, Breast Cancer - Palliative, Tykerb, Osteolytic Bone Metastases of Breast Cancer, Lapatinib, Trastuzumab

Women Often Overestimate Odds That Early Breast Cancer Will Return, Spread

Posted 4 Mar 2016 by Drugs.com

THURSDAY, March 3, 2016 – Many women treated for early breast cancer overestimate the odds of it spreading to another organ, and those fears can diminish their quality of life, new research suggests. The study involved more than 1,000 women newly diagnosed with either very early breast cancer, known as DCIS (ductal carcinoma in situ), or low-risk invasive cancer (LRI). All were at low risk for what's called distant recurrence – cancer spreading to organs throughout the body. But more than one-third of those with DCIS and one quarter of those with low-risk invasive tumors overestimated their risk for distant recurrence, said Sarah Hawley, a professor of medicine at the University of Michigan School of Medicine. Even women with a very favorable outlook after treatment significantly misjudged their risks, Hawley said. "They provided a risk number estimate more than double their actual ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer

Breast Cancer Survivors Vulnerable for Thyroid Tumors, and Vice Versa: Study

Posted 5 Feb 2016 by Drugs.com

FRIDAY, Feb. 5, 2016 – Women who survive breast or thyroid cancer are linked to an increased risk for the other, according to a new analysis. University of Chicago researchers who reviewed 37 published studies found breast cancer survivors were 1.55 times more likely to develop thyroid cancer than women who hadn't had breast cancer. And, female thyroid cancer survivors were 1.18 times more likely to get breast cancer than women who hadn't had thyroid cancer, researchers said. "This is a real risk," said study lead author Dr. Raymon Grogan, director of the university's endocrine surgery research program. "People who have had one of these cancers need to be aware that they are at higher risk for developing the other cancer," he said. Thyroid cancer cases have nearly tripled in the United States over the past 30 years, and breast cancer is the most common cancer among women, according to ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Breast Cancer, Prevention, Breast Cancer - Palliative, Thyroid Tumor, Osteolytic Bone Metastases of Breast Cancer

Early Chemo Less Likely to Help Black Breast Cancer Patients: Study

Posted 12 Dec 2015 by Drugs.com

FRIDAY, Dec. 11, 2015 – Early chemotherapy is less likely to benefit black women with breast cancer than those in other racial and ethnic groups, a new study finds. Advanced breast cancer is more common among black, Hispanic and Asian women than it is in white women. As a result, black women often receive chemotherapy before surgery in an effort to improve their outcomes, the Yale University Cancer Center researchers said. But their study of 27,300 women with stage 1 to 3 breast cancer showed that early (neoadjuvant) chemotherapy was less effective in black patients than in other women. "Even when we controlled for the fact that minority women often present with more advanced-stage, higher-grade tumors, and more aggressive types of breast cancer overall, our team was surprised to find that black women did not respond as well to neoadjuvant chemotherapy compared to other racial groups," ... Read more

Related support groups: Provera, Depo-Provera, Breast Cancer, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Lupron Depot, Femara, Breast Cancer, Metastatic, Anastrozole, Evista, Zoladex, Megestrol, Letrozole, Megace, Aromasin, Herceptin, Exemestane, Breast Cancer - Adjuvant

Two Drugs Equal in Preventing Early Breast Cancer's Return: Study

Posted 11 Dec 2015 by Drugs.com

FRIDAY, Dec. 11, 2015 – Postmenopausal women who have an early, noninvasive form of breast cancer had similar recurrence rates of disease whether they took the drug tamoxifen or the aromatase inhibitor anastrozole after surgery, new research shows. However, the side effects of the two medications differed greatly, said study author Jack Cuzick, director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London, England. His team looked at nearly 3,000 women, all past menopause, who had hormone-receptor positive ductal carcinoma in situ (DCIS) breast cancer and underwent surgery to excise it. With DCIS, the cells that line the milk ducts have changed but not spread into the surrounding breast tissue. Half the women were randomly assigned to take 1 milligram (mg) a day of anastrozole (Arimidex), while the other half took 20 mg a day of tamoxifen (Nolvadex). Each ... Read more

Related support groups: Provera, Depo-Provera, Breast Cancer, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Lupron Depot, Femara, Breast Cancer, Metastatic, Anastrozole, Evista, Zoladex, Megestrol, Letrozole, Megace, Aromasin, Herceptin, Exemestane, Breast Cancer - Adjuvant

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Breast Cancer

Related Drug Support Groups

pamidronate, Aredia